Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

LM. Hofstra, N. Sauvageot, J. Albert, I. Alexiev, F. Garcia, D. Struck, DA. Van de Vijver, B. Åsjö, D. Beshkov, S. Coughlan, D. Descamps, A. Griskevicius, O. Hamouda, A. Horban, M. Van Kasteren, T. Kolupajeva, LG. Kostrikis, K. Liitsola, M....

. 2016 ; 62 (5) : 655-63. [pub] 20151129

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000832

BACKGROUND: Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. METHODS: Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. RESULTS: The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%-9.5%) in 2008-2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. CONCLUSIONS: Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected.

AP HP Groupe hospitalier Bichat Claude Bernard IAME INSERM UMR 1137 Université Paris Diderot Sorbonne Paris Cité Paris France

Complejo Hospitalario Universitario de Granada Instituto de Investigación IBS Granada

Department of Infectious Diseases National Institute for Health and Welfare Helsinki Finland

Department of Virology University Medical Center Utrecht The Netherlands

Erasmus MC University Medical Center Rotterdam The Netherlands

Faculty of Medicine Slovenian HIV AIDS Reference Centre University of Ljubljana Slovenia

Faculty of Medicine University of Belgrade Serbia

Hospital of Infectious Diseases Warsaw Poland

Infectiology Center of Latvia Riga

IrsiCaixa Foundation Badalona Spain

Karolinska Institute Solna Karolinska University Hospital Stockholm Sweden

Lithuanian AIDS Center Vilnius Lithuania

Luxembourg Institute of Health Luxembourg

Luxembourg Institute of Health Luxembourg Department of Virology University Medical Center Utrecht The Netherlands

Medical University Vienna Austria

National Center of Infectious and Parasitic Diseases Sofia Bulgaria

National HIV Reference Laboratory Chaim Sheba Medical Center Tel Hashomer Israel

National Institute for Infectious Diseases Prof dr Matei Bals Bucharest Romania

National Reference Laboratory for HIV AIDS National Institute of Public Health Prague Czech Republic

National Retrovirus Reference Center University of Athens Greece

on behalf of Cohorte de Adultos de la Red de Investigación en SIDA Spain

Rega Institute for Medical Research KU Leuven Belgium

Robert Koch Institute Berlin Germany

Slovak Medical University Bratislava Slovakia

St Elisabeth Hospital Tilburg The Netherlands

Statens Serum Institut Copenhagen Denmark

University College Dublin Ireland

University Hospital for Infectious Diseases Dr Fran Mihaljevic Zagreb Croatia

University of Bergen Norway

University of Cyprus Nicosia

University of Siena Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000832
003      
CZ-PrNML
005      
20170113121753.0
007      
ta
008      
170103s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/cid/civ963 $2 doi
024    7_
$a 10.1093/cid/civ963 $2 doi
035    __
$a (PubMed)26620652
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hofstra, L Marije $u Luxembourg Institute of Health, Luxembourg Department of Virology, University Medical Center Utrecht, The Netherlands.
245    10
$a Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe / $c LM. Hofstra, N. Sauvageot, J. Albert, I. Alexiev, F. Garcia, D. Struck, DA. Van de Vijver, B. Åsjö, D. Beshkov, S. Coughlan, D. Descamps, A. Griskevicius, O. Hamouda, A. Horban, M. Van Kasteren, T. Kolupajeva, LG. Kostrikis, K. Liitsola, M. Linka, O. Mor, C. Nielsen, D. Otelea, D. Paraskevis, R. Paredes, M. Poljak, E. Puchhammer-Stöckl, A. Sönnerborg, D. Staneková, M. Stanojevic, K. Van Laethem, M. Zazzi, S. Zidovec Lepej, CA. Boucher, JC. Schmit, AM. Wensing, . ,
520    9_
$a BACKGROUND: Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. METHODS: Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. RESULTS: The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%-9.5%) in 2008-2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. CONCLUSIONS: Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected.
650    _2
$a dospělí $7 D000328
650    _2
$a látky proti HIV $x farmakologie $7 D019380
650    _2
$a virová léková rezistence $x genetika $7 D024882
650    _2
$a Evropa $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HIV infekce $x farmakoterapie $x virologie $7 D015658
650    _2
$a inhibitory HIV-proteasy $x farmakologie $7 D017320
650    _2
$a HIV-1 $x účinky léků $x genetika $7 D015497
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a prevalence $7 D015995
650    _2
$a inhibitory reverzní transkriptasy $x farmakologie $7 D018894
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sauvageot, Nicolas $u Luxembourg Institute of Health, Luxembourg.
700    1_
$a Albert, Jan $u Karolinska Institute, Solna Karolinska University Hospital, Stockholm, Sweden. $7 gn_A_00003446
700    1_
$a Alexiev, Ivailo $u National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria. $7 gn_A_00004031
700    1_
$a Garcia, Federico $u Complejo Hospitalario Universitario de Granada, Instituto de Investigación IBS Granada; on behalf of Cohorte de Adultos de la Red de Investigación en SIDA, Spain.
700    1_
$a Struck, Daniel $u Luxembourg Institute of Health, Luxembourg.
700    1_
$a Van de Vijver, David A M C $u Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
700    1_
$a Åsjö, Birgitta $u University of Bergen, Norway.
700    1_
$a Beshkov, Danail $u National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
700    1_
$a Coughlan, Suzie $u University College Dublin, Ireland.
700    1_
$a Descamps, Diane $u AP-HP Groupe hospitalier Bichat-Claude Bernard, IAME INSERM UMR 1137, Université Paris Diderot Sorbonne Paris Cité, Paris, France.
700    1_
$a Griskevicius, Algirdas $u Lithuanian AIDS Center, Vilnius, Lithuania.
700    1_
$a Hamouda, Osamah $u Robert Koch Institute, Berlin, Germany.
700    1_
$a Horban, Andrzej $u Hospital of Infectious Diseases, Warsaw, Poland.
700    1_
$a Van Kasteren, Marjo $u St Elisabeth Hospital, Tilburg, The Netherlands.
700    1_
$a Kolupajeva, Tatjana $u Infectiology Center of Latvia, Riga.
700    1_
$a Kostrikis, Leondios G $u University of Cyprus, Nicosia.
700    1_
$a Liitsola, Kirsi $u Department of Infectious Diseases, National Institute for Health and Welfare, Helsinki, Finland.
700    1_
$a Linka, Marek $u National Reference Laboratory for HIV/AIDS, National Institute of Public Health, Prague, Czech Republic.
700    1_
$a Mor, Orna $u National HIV Reference Laboratory, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
700    1_
$a Nielsen, Claus $u Statens Serum Institut, Copenhagen, Denmark.
700    1_
$a Otelea, Dan $u National Institute for Infectious Diseases "Prof. dr. Matei Bals", Bucharest, Romania.
700    1_
$a Paraskevis, Dimitrios $u National Retrovirus Reference Center, University of Athens, Greece.
700    1_
$a Paredes, Roger $u IrsiCaixa Foundation, Badalona, Spain.
700    1_
$a Poljak, Mario $u Faculty of Medicine, Slovenian HIV/AIDS Reference Centre, University of Ljubljana, Slovenia.
700    1_
$a Puchhammer-Stöckl, Elisabeth $u Medical University Vienna, Austria.
700    1_
$a Sönnerborg, Anders $u Karolinska Institute, Solna Karolinska University Hospital, Stockholm, Sweden.
700    1_
$a Staneková, Danica $u Slovak Medical University, Bratislava, Slovakia.
700    1_
$a Stanojevic, Maja $u Faculty of Medicine, University of Belgrade, Serbia.
700    1_
$a Van Laethem, Kristel $u Rega Institute for Medical Research, KU Leuven, Belgium.
700    1_
$a Zazzi, Maurizio $u University of Siena, Italy.
700    1_
$a Zidovec Lepej, Snjezana $u University Hospital for Infectious Diseases "Dr. Fran Mihaljevic", Zagreb, Croatia.
700    1_
$a Boucher, Charles A B $u Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
700    1_
$a Schmit, Jean-Claude $u Luxembourg Institute of Health, Luxembourg.
700    1_
$a Wensing, Annemarie M J $u Department of Virology, University Medical Center Utrecht, The Netherlands.
700    1_
$a ,
773    0_
$w MED00001133 $t Clinical infectious diseases an official publication of the Infectious Diseases Society of America $x 1537-6591 $g Roč. 62, č. 5 (2016), s. 655-63
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26620652 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170113121854 $b ABA008
999    __
$a ok $b bmc $g 1179972 $s 961399
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 62 $c 5 $d 655-63 $e 20151129 $i 1537-6591 $m Clinical infectious diseases $n Clin Infect Dis $x MED00001133
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace